VISTA blockade has been shown to reduce tumor growth in several preclinical tumor models 14, 15, 18, 19, while in human cancers VISTA expression on tumor-infiltrating myeloid cells and T-cells has been associated with therapeutic resistance and recurrence 9, 20-23. This evidence concerns the gene VSIR and neoplasm.